Brentuximab Vedotin Approved in Europe for CTCL

January 22, 2018 – Brentuximab vedotin has been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. The approval of the antibody-drug conjugate is based on results from the phase III ALCANZA trial, in which brentuximab vedotin induced responses lasting at least 4 months in 56.3% of patients compared with 12.5% in patients receiving physician’s choice of … (leggi tutto)